MX2022001063A - Derivados de alcohol como abridores del canal de potasio kv7. - Google Patents

Derivados de alcohol como abridores del canal de potasio kv7.

Info

Publication number
MX2022001063A
MX2022001063A MX2022001063A MX2022001063A MX2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A
Authority
MX
Mexico
Prior art keywords
potassium channel
alcohol derivatives
channel openers
compounds
potassium channels
Prior art date
Application number
MX2022001063A
Other languages
English (en)
Inventor
Anette Graven Sams
Jian Hong
Mario Rottländer
Krestian Larsen
Xiaofang Wang
Debasis Das
Shu Hui Chen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2022001063A publication Critical patent/MX2022001063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona compuestos novedosos que activan los canales de potasio Kv7. Los diferentes aspectos de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y usos de los compuestos para tratar trastornos que responden a la activación de los canales de potasio Kv7.
MX2022001063A 2019-08-02 2020-07-30 Derivados de alcohol como abridores del canal de potasio kv7. MX2022001063A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19189750 2019-08-02
CN201910734123 2019-08-09
EP19191887 2019-08-15
PCT/EP2020/071520 WO2021023617A1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers

Publications (1)

Publication Number Publication Date
MX2022001063A true MX2022001063A (es) 2022-02-14

Family

ID=71894829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001063A MX2022001063A (es) 2019-08-02 2020-07-30 Derivados de alcohol como abridores del canal de potasio kv7.

Country Status (18)

Country Link
EP (1) EP4007634A1 (es)
JP (1) JP2022543203A (es)
KR (1) KR20220041084A (es)
CN (1) CN114206830A (es)
AU (1) AU2020325517A1 (es)
BR (1) BR112021006324A2 (es)
CA (1) CA3148719A1 (es)
CL (1) CL2022000221A1 (es)
CO (1) CO2022000080A2 (es)
CR (1) CR20220028A (es)
DO (1) DOP2022000026A (es)
EC (1) ECSP22008993A (es)
IL (1) IL290193A (es)
JO (1) JOP20220017A1 (es)
MX (1) MX2022001063A (es)
PE (1) PE20220345A1 (es)
WO (1) WO2021023617A1 (es)
ZA (1) ZA202109598B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290167A1 (en) 2000-05-26 2003-03-12 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
AU2001268303A1 (en) 2000-06-11 2001-12-24 Du Pont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
EA017915B1 (ru) 2006-02-07 2013-04-30 Х. Лундбекк А/С Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
EA201070189A1 (ru) 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
HUE063567T2 (hu) * 2018-02-20 2024-01-28 H Lundbeck As Alkoholszármazékok mint KV7 káliumcsatorna nyitók

Also Published As

Publication number Publication date
ZA202109598B (en) 2024-04-24
AU2020325517A1 (en) 2022-02-24
CN114206830A (zh) 2022-03-18
CO2022000080A2 (es) 2022-01-17
KR20220041084A (ko) 2022-03-31
DOP2022000026A (es) 2022-03-31
EP4007634A1 (en) 2022-06-08
CL2022000221A1 (es) 2022-10-07
IL290193A (en) 2022-03-01
CR20220028A (es) 2022-03-02
JOP20220017A1 (ar) 2023-01-30
WO2021023617A1 (en) 2021-02-11
BR112021006324A2 (pt) 2022-02-15
JP2022543203A (ja) 2022-10-11
ECSP22008993A (es) 2022-03-31
PE20220345A1 (es) 2022-03-14
CA3148719A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
EP4241843A3 (en) Alcohol derivatives as kv7 potassium channel openers
MX2019009358A (es) Anticuerpo anti-gprc5d y molecula que comprende el anticuerpo.
EA201790806A1 (ru) Иммунорегулирующие средства
AU2015262993B2 (en) Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
WO2018237037A3 (en) HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2018014114A (es) Derivados del sobetiroma.
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
AU2014324961A8 (en) Highly potent glucocorticoids
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021004935A (es) Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3.
ZA202109598B (en) Alcohol derivatives as kv7 potassium channel openers
AU2018279184A1 (en) Anti-TrkB antibodies
MA43158B1 (fr) Composés oxa-diazadispiro possédant une activité contre la douleur
MX2022001805A (es) Formulaciones de anticuerpos anti-esclerostina.
WO2020086650A3 (en) Novel compounds
MX2021011364A (es) Inhibidores del canal de potasio novedosos.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
MX2023003306A (es) Inhibidores del canal de potasio novedosos.